MALVERN, Pa.--()--TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the poster presentation of preclinical data on its Smac mimetic drug candidate birinapant at the 54th ASH Annual Meeting and Exposition in Atlanta, Georgia. Birinapant has entered Phase 2 clinical trials for several solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing.
“Birinapant (TL32711), a small molecule Smac Mimetic, induces regressions in Childhood Acute Lymphoblastic Leukemia (ALL) Xenografts that express TNFα and Syngergizes with TNFα in Vitro – A report from the Pediatric Preclinical Testing Program (PPTP)”
In a poster entitled “Birinapant (TL32711), a small molecule Smac Mimetic, induces regressions in Childhood Acute Lymphoblastic Leukemia (ALL) Xenografts that express TNFα and Syngergizes with TNFα in Vitro – A report from the Pediatric Preclinical Testing Program (PPTP)” (Abstract # 3565), birinapant induced regressions in 2 of 3 ALL xenografts, with one of these showing a maintained complete response (CR). TNFα is mechanistically associated with the activity of Smac mimetics, and the NCI’s PPTP data for ALL xenografts are consistent with a relationship between TNFα expression and responsiveness to birinapant. The PPTP results demonstrate that birinapant shows activity against a subset of childhood ALL, and additional in vivo testing is ongoing to better identify predictive markers that can reliably identify responsive cases. Among solid tumor cell lines, potentiation of birinapant activity was observed for selected rhabdomyosarcoma, rhabdoid tumor, Ewing sarcoma, and neuroblastoma cell lines with the addition of either TNFα or TRAIL.
Birinapant (formerly TL32711) is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) that selectively antagonizes the Inhibitor of Apoptosis (IAP) Proteins. Birinapant rapidly degrades IAPs and enables TNFα and TRAIL to activate the extrinsic apoptosis pathway, while it rapidly turns off the canonical NF-κB survival pathway, causing cancer cell death. Birinapant has entered Phase 2 clinical development for several solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing. In clinical studies to date, birinapant has been well tolerated and demonstrated effective suppression of IAPs and anti-cancer activity.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that is developing Smac mimetics, small molecule drugs that mimic Smac for the treatment of cancers. The company’s institutional investors include Clarus Ventures, HealthCare Ventures, Quaker Partners, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company’s Web site at www.tetralogicpharma.com.